Verition Fund Management
ADPT icon

Verition Fund Management’s Adaptive Biotechnologies ADPT Stock Holding History

Verition Fund Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-85,334
Closed -$1.28M – 3470
2025
Q3 		$1.28M Sell
85,334
-390,305
-82% -$4.76M 0.01% 2341
2025
Q2 		$5.54M Buy
475,639
+399,991
+529% +$3.63M 0.02% 1003
2025
Q1 		$562K Buy
75,648
+52,858
+232% +$406K ﹤0.01% 2513
2024
Q4 		$137K Sell
22,790
-20,175
-47% -$111K ﹤0.01% 3042
2024
Q3 		$220K Sell
42,965
-15,392
-26% -$67.1K ﹤0.01% 2822
2024
Q2 		$211K Buy
58,357
+38,642
+196% +$123K ﹤0.01% 2560
2024
Q1 		$63.3K Buy
+19,715
New +$76.3K ﹤0.01% 2621
2022
Q4 		– Sell
-22,612
Closed -$161K – 2075
2022
Q3 		$161K Buy
+22,612
New +$213K ﹤0.01% 2535
2021
Q2 		– Sell
-5,198
Closed -$209K – 1853
2021
Q1 		$209K Buy
+5,198
New +$281K ﹤0.01% 1320

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Verition Fund Management's ADPT Position: Q4 2025 in Review

Verition Fund Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 85,334 shares — an estimated $1.28M sold.

Verition Fund Management first reported a position in ADPT in Q1 2021 and held it in 9 quarters. The position peaked at $5.54M in Q2 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Verition Fund Management reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 85,334 Adaptive Biotechnologies shares in Q4 2025, an estimated $1.28M.
  • Verition Fund Management first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 9 quarters.
  • Verition Fund Management's Adaptive Biotechnologies position peaked at $5.54M in Q2 2025.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.